Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020 Jun; 181(2):391-401.
-
Adult
-
Biomarkers, Tumor
-
Breast Neoplasms
-
Carcinoma, Ductal, Breast
-
Carcinoma, Lobular
-
Female
-
Follow-Up Studies
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Middle Aged
-
Neoplasm Invasiveness
-
Neoplasm Recurrence, Local
-
Peptide Fragments
-
Prognosis
-
Prospective Studies
-
Receptor, ErbB-2
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Single-Blind Method
-
Survival Rate
-
Vaccines, Subunit